Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial.

9027Background: In the Phase III AURA3 trial (NCT02151981), osimertinib, a third-generation EGFR-TKI, had significantly greater efficacy than platinum-pemetrexed in patients (pts) with advanced NSC...